Stockscreener 앱 받기
97.46
4.07%
-4.13
시간 외 거래:
97.46
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
How cyclical is Rhythm Pharmaceuticals Inc. (1RV) stock compared to rivalsJuly 2025 Reactions & High Win Rate Trade Tips - ulpravda.ru
How Rhythm Pharmaceuticals Inc. stock reacts to oil prices2025 Fundamental Recap & Community Verified Trade Alerts - ulpravda.ru
CEO Moves: Why Rhythm Pharmaceuticals Inc. (1RV) stock fits value portfolios2025 Biggest Moves & Advanced Swing Trade Entry Alerts - ulpravda.ru
Rhythm Pharmaceuticals, Inc. (RYTM): Analyst Consensus and Growth Potential Amidst a 32% Upside - DirectorsTalk Interviews
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates - MSN
Understanding the Setup: (RYTM) and Scalable Risk - Stock Traders Daily
Is Rhythm Pharmaceuticals Inc a good long term investmentEconomic Indicators Overview & No Fee. No Catch. Just Smart Investment Ideas - earlytimes.in
What Technical Indicators Signal for BLS E Next MonthCandlestick Trading Patterns & Identify Breakout Stocks - earlytimes.in
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling - FinancialContent
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus - ts2.tech
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 3.3%Should You Sell? - MarketBeat
Rhythm Pharmaceuticals Earnings Notes - Trefis
Rhythm advances lead asset into late-stage trial in Prader-Willi syndrome - MSN
Rhythm Pharma’s Rare-Obesity Drug Keeps Growth Rolling - Finimize
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rhythm Pharmaceuticals (RYTM) Stock Analysis: Exploring a 26% Upside Potential in Biotech - DirectorsTalk Interviews
Does Rhythm Pharmaceuticals (NASDAQ:RYTM) Have A Healthy Balance Sheet? - 富途牛牛
Harbor Capital Advisors Inc. Has $3.76 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (FRA:1RV) OCF Margin % : -51.90% (As of Sep. 2025) - GuruFocus
Rhythm Pharmaceuticals (FRA:1RV) EV-to-FCF : -62.60 (As of Dec. 25, 2025) - GuruFocus
Rhythm Pharmaceuticals (FRA:1RV) EV-to-OCF : -62.60 (As of Dec. 25, 2025) - GuruFocus
Why (RYTM) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on PWS trial data - Investing.com Canada
RYTM: HC Wainwright Raises Price Target for Rhythm Pharmaceutica - GuruFocus
Voya Investment Management LLC Has $22.38 Million Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
HC Wainwright & Co. Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
With Rhythm Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis
What is the fair value estimate for Rhythm Pharmaceuticals Inc. (1RV) stock in 2025Earnings Growth Summary & Weekly High Return Stock Opportunities - Улправда
How Rhythm Pharmaceuticals Inc. stock performs in weak economy2025 Major Catalysts & Safe Capital Allocation Plans - Улправда
Assenagon Asset Management S.A. Sells 13,870 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
How institutional buying supports Rhythm Pharmaceuticals Inc. stockWeekly Trade Report & Low Drawdown Momentum Trade Ideas - ulpravda.ru
Is Rhythm Pharmaceuticals Inc. (1RV) stock a top dividend aristocrat candidateJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - Улправда
Shorts Report: Is Rhythm Pharmaceuticals Inc. (1RV) stock a top dividend aristocrat candidate2025 Technical Patterns & Daily Growth Stock Tips - Улправда
Can Rhythm Pharmaceuticals Inc. stock reach $100 price targetRecession Risk & Fast Exit Strategy with Risk Control - ulpravda.ru
How Rhythm Pharmaceuticals Inc. stock performs in rate cut cycles2025 Price Targets & High Win Rate Trade Alerts - Улправда
Guggenheim Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next StepsSlideshow (NASDAQ:RYTM) 2025-12-17 - Seeking Alpha
Guggenheim Raises Price Target for Rhythm Pharmaceuticals (RYTM) to $140 | RYTM Stock News - GuruFocus
Pamela Cramer Sells 3,350 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock - MarketBeat
Rhythm Pharmaceuticals Executive Sells Shares - TradingView — Track All Markets
FDA Action Alert: GSK, Aldeyra, Rhythm and More - BioSpace
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Rhythm Pharmaceuticals (RYTM) - The Globe and Mail
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $167.00 at Citizens Jmp - MarketBeat
Rhythm Pharmaceuticals stock rises after positive study data for setmelanotide in treating genetic disorder - MSN
Alkeon Capital Management LLC Grows Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Citizens Maintains Rhythm Pharmaceuticals (RYTM) Market Outperform Recommendation - Nasdaq
Canaccord Genuity Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
RYTM Stock: Canaccord Genuity Raises Price Target to $141, Maint - GuruFocus
Goldman Sachs Raises Price Target for RYTM to $157, Maintains Bu - GuruFocus
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN
Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on positive PWS data - Investing.com Canada
Rhythm Pharma Surprises With Encouraging PWS Drug Trial Results - Finimize
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says - marketscreener.com
RYTM Analyst Rating Update: Citizens Raises Price Target to $167 - GuruFocus
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Optimism - MSN
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $150 From $129, Keeps Overweight Rating - marketscreener.com
0.80%
4.56%
자본화:
|
볼륨(24시간):